Wall Street brokerages expect that Unum Therapeutics Inc (NASDAQ:UMRX) will report $3.10 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Unum Therapeutics’ earnings, with the highest sales estimate coming in at $4.41 million and the lowest estimate coming in at $1.80 million. Unum Therapeutics reported sales of $1.67 million in the same quarter last year, which indicates a positive year-over-year growth rate of 85.6%. The firm is expected to announce its next quarterly earnings report on Monday, August 12th.
On average, analysts expect that Unum Therapeutics will report full-year sales of $13.82 million for the current year, with estimates ranging from $8.30 million to $17.60 million. For the next fiscal year, analysts anticipate that the company will post sales of $16.91 million, with estimates ranging from $9.00 million to $25.33 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Unum Therapeutics.
Unum Therapeutics (NASDAQ:UMRX) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.08). Unum Therapeutics had a negative net margin of 373.81% and a negative return on equity of 62.24%. The business had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.15 million.
Shares of Unum Therapeutics stock opened at $2.32 on Wednesday. The firm has a 50-day simple moving average of $3.06. Unum Therapeutics has a 52 week low of $2.28 and a 52 week high of $17.66. The stock has a market capitalization of $71.98 million, a P/E ratio of -1.67 and a beta of 1.75. The company has a quick ratio of 2.65, a current ratio of 2.65 and a debt-to-equity ratio of 0.11.
Large investors have recently bought and sold shares of the stock. Wasatch Advisors Inc. raised its position in Unum Therapeutics by 64.5% in the first quarter. Wasatch Advisors Inc. now owns 254,449 shares of the company’s stock valued at $1,117,000 after purchasing an additional 99,814 shares during the period. Rhumbline Advisers purchased a new stake in Unum Therapeutics in the first quarter valued at approximately $85,000. Deutsche Bank AG raised its position in Unum Therapeutics by 72.4% in the fourth quarter. Deutsche Bank AG now owns 63,657 shares of the company’s stock valued at $279,000 after purchasing an additional 26,742 shares during the period. D. E. Shaw & Co. Inc. raised its position in Unum Therapeutics by 7.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 54,956 shares of the company’s stock valued at $242,000 after purchasing an additional 3,846 shares during the period. Finally, Bank of America Corp DE raised its position in Unum Therapeutics by 11.6% in the fourth quarter. Bank of America Corp DE now owns 99,545 shares of the company’s stock valued at $438,000 after purchasing an additional 10,317 shares during the period. Institutional investors own 47.27% of the company’s stock.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Read More: Diversification Important in Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.